drugset / Trial / NCT02403895

AZD2014 and Weekly Paclitaxel in Squamous NSCLC

NCT02403895

Phase 2 Terminated 11 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)

Timeline

Start
2015-04-15
Primary completion
2016-12-29
Completion
2016-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2
Subject Vistusertib Small molecule 50 mg Oral